Our Studies/ Scientific Programs

The intestinal microbiota are highly functional, with a combined genome (termed the microbiome) that is approximately 130-160 times larger than the human or canine genome. The microbiome is a highly functional organ and produces approximately 1,000 different metabolites, many of which have systemic effects in the dog. Intestinal dysbiosis is defined as an alteration in

Despite years of active research in the field, high mortality rates associated with sepsis have remained unchanged over the last three decades; we aim to change this!

Following removal of the primary tumor and adjuvant chemotherapy, the development of lung metastasis is the most common cause of mortality in dogs with osteosarcoma. A distinctive feature of lung metastases of osteosarcoma in human patients is the surprising benefit that can result from surgical resection of the lung nodules. The use of surgery to

Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against  several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second drug, Encequidar, which improves this issue of poor

We propose that the spontaneous, but strongly genetic-based model of canine Necrotizing meningoencephalitis (NME) presents a unique way to help demonstrate the feasibility of inflammatory neurological disease prevention therapy.

Neutropenia (low white blood cell count) is a common side effect of chemotherapy in patients with cancer, with sepsis being a potential consequence. The timely identification and treatment of sepsis is paramount to the success of therapy.

Hemangiosarcoma (HSA) is an aggressive cancer in dogs and carries a poor prognosis. There are limited therapeutic options for the treatment of HSA, with none currently providing a significant opportunity for long-term survival.

This study is looking to evaluate the pharmacology profile of CBD in dogs (i.e. how it’s processed in the body) as well as its effectiveness in treating pain in dogs with chronic osteoarthritis. This study will hopefully result in similar studies being conducted in the fields of Neurology and Oncology.

This study seeks to understand the intestinal absorption potential of a novel formulation of rapamycin when administered to dogs with naturally occurring cancer. The data from this study will be used to define an ideal dose of the drug to use in future cancer clinical studies.

We have previously reported on the tolerability and hints of clinical activity of Sorafenib in dogs with cancer. This background provides a rationale for the further study of Sorafenib in dogs with cancer. In this study we seek to define an optimal dosing schedule for Sorafenib and will assess its tolerability and activity in dogs with solid tumors.

Is your dog undergoing surgery for a ruptured splenic tumor? Ethos Discovery would love to have you and your dog participate in our clinical trial! We are evaluating drugs for the treatment of HSA with the goal of curing this aggressive cancer.

This study aims to determine whether or not canine patients diagnosed with canine osteosarcoma (OSA) have intestinal dysbiosis and whether treating intestinal disease improves patient outcomes.